

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen
312-265-9574
bsorensen@zacks.com

scr.zacks.com

101 N. Wacker Drive, Chicago, IL 60606

Bone Biologics

(BBLG-NASDAQ)

BBLG: Making Major Step Toward Commercialization

BBLG continues to pursue a way to make bone regeneration more efficient and with better outcomes for patients. We value BBLG at \$22.50 per share using the discounted cash flow method.

Outlook

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.

The company continues with human trials and reported 2Q2025 financial results that showed good cash balances that should allow testing results to bolster BBLG.

Current Price (08/14/25) \$2.35
Valuation **\$22.50**

SUMMARY DATA

52-Week High **\$15.18**
52-Week Low **\$2.33**
One-Year Return (%) **-73.35**
Beta **0.66**
Average Daily Volume (sh) **55,906**

Shares Outstanding (mil) **1**
Market Capitalization (\$mil) **\$1**
Short Interest Ratio (days) **N/A**
Institutional Ownership (%) **34**
Insider Ownership (%) **6**

Annual Cash Dividend **\$0.00**
Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates
Sales (%) **N/A**
Earnings Per Share (%) **N/A**
Dividend (%) **N/A**

Risk Level **High**
Type of Stock **Small-Value**
Industry **Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(in millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2022	0 A	0 A	0 A	0 A	0 A
2023	0 A	0 A	0 A	0 A	0 A
2024	0 A	0 A	0 A	0 A	0 A
2025	0 A	0 A	0 E	0 E	0 E

Earnings per share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2022	-0.07 A	-0.05 A	-0.12 A	-0.02 A	-0.13 A*
2023	-0.23 A	-1.69 A	-0.61 A	-5.89 A	-34.01 A
2024	-1.31 A	-0.67 A	-2.37 A	-1.00 A	-4.83 A
2025	-0.32 A	-1.33 A	-1.23 E	-1.14 E	-4.02 E

* Quarterly numbers don't add to annual due to share issuance and reverse split.

COMPANY UPDATE

Bone Biologics is a company developing products for spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available, at least preliminary data, in the coming year. Given the preclinical studies that we've reported on extensively, we are optimistic that exciting results will be forthcoming that will positively impact the lives of thousands of spinal injury patients.

The company recently released its 2Q2025 financial results that showed a loss of \$1.33 per share, in line with estimates but saw cash grow to \$6.3 million. For a clinical stage company, having cash on hand is vital and the company notes that it has enough cash to finance operations into the second quarter of 2026, which gives us comfort as we await test results from the trial discussed below.

Late last year, the company announced an important milestone—the first two human patients have been treated in the company's NB1 bone graft device. This marks the start of the pilot clinical study that will evaluate NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD) and will evaluate safety and effectiveness, fusion success, pain, function improvement and adverse events. According to the company, in order to be enrolled in the study, patients must have DDD at one level from L2-S1 and may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level. These two initial patients were treated in Australia. As we've noted before, the study design was previously reviewed and agreed upon by the U.S. Food and Drug Administration's Division of Orthopedic Devices in a Pre-submission to support progression to a pivotal clinical trial in the United States.

There are approximately 350,000 spinal fusion surgeries done in the US every year with varying degrees of success in alleviating often debilitating back pain. The existing dominant technology, known as rhBMP, has been quite successful in advancing the spinal fusion procedure but there are also challenges that can come along with using that technology. Patients can experience such impacts as rapid, uncontrolled bone growth that causes an unsound structure and unwanted bone formation where bone will grow where it is not intended. Back pain impacts 65 million Americans, with 16 million of those having what would be considered chronic back pain, leading to an estimated \$12 billion per year in health care and indirect cost according to the Georgetown Policy Institute. While spinal fusion surgery isn't the appropriate treatment for every kind of back pain, it can help to relieve the pain associated with a variety of conditions.

The NELL-1 technology at the heart of NB1 is the centerpiece of what Bone Biologics is developing. It was developed by UCLA TDG and Bone holds the exclusive worldwide rights to that technology. NELL-1 has been reviewed positively in over 45 peer reviewed publications demonstrating technological viability. NELL-1 has shown spine fusion effectiveness across three animal species—rodent, sheep and nonhuman primate and has competed two clinically relevant sheep studies that demonstrated NELL-1 increases the fusion rate and quantity of bone compared to the control group.


Summary

We have written before about the market opportunity that BBLG has, and it continues to grow. If trial results are positive, as we believe they will be, the positive reaction in the investing community will likely be swift. We continue to be excited about the opportunity and the science behind NELL-1 and are looking forward to the results from the human trials ongoing this year. BBLG has what we believe is a product with great potential, addressing a market with seemingly insatiable demand and a solid funding situation, which is vital in this environment. As such, we believe investors with a longer-term investing horizon should take a look at BBLG.

INCOME STATEMENT AND BALANCE SHEET

Bone Biologics Income Statement and Balance Sheet										
	1Q2024A	2Q2024A	3Q2024A	4Q2024A	1Q2025A	2Q2025A	3Q2025E	4Q2025E	2026E	
Revenues	0	0	0	0	0	0	0	0	0	0
Cost of Good Sold	0	0	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Expenses										
Research and Dev.	245,625	350,442	429,747	1,104,571	423,576	191,608	195,440	199,349	766,432	
Gen. and Admin.	657,911	459,223	521,274	450,368	614,910	556,467	567,596	578,948	2,225,868	
Total Operating Expenses	903,536	809,665	951,021	1,554,939	1,038,486	748,075	763,037	778,297	2,992,300	
Loss From Operations	(903,536)	(809,665)	(951,021)	(1,554,939)	(1,038,486)	(748,075)	(763,037)	(778,297)	(2,992,300)	
Interest income (expense)	255	15,147	19,993	15,686	20,039	6,654	6,787	6,923	26,616	
Other income/(expenses)	37,311	10,785	(9,974)	17,538	1,355	902	920	938	3,608	
Loss before provision for income taxes	(865,970)	(783,733)	(941,002)	(1,521,715)	(1,017,092)	(740,519)	(755,329)	(770,436)	(2,962,076)	
Provision for Income taxes	0	0	0	0	0	0	0	0	0	
Net loss	(865,970)	(783,733)	(941,002)	(1,521,715)	(1,017,092)	(740,519)	(755,329)	(770,436)	(2,962,076)	
Deemed dividend on warrant inducements	0	0	(3,212,504)	0	1	0	0	0	0	
Net loss per share	(\$1.31)	(\$0.67)	(\$2.37)	(\$1.00)	(\$0.32)	(\$1.33)	(\$1.23)	(\$1.14)	(\$3.99)	
Wtd Avg Shares Outstanding	660,928	1,168,423	1,753,409	1,517,235	3,183,191	557,787	613,566	674,922	742,414	
Assets										
Current Assets										
Cash	3,227,634	2,332,068	3,566,426	3,325,131	2,746,555	6,640,468	6,308,445	5,993,022	5,693,371	
Advances on R&D contract services	328,844	650,275	385,742	258,059	263,220	208,972	213,151	217,414	221,763	
Prepaid Expenses	283,096	211,121	113,650	278,179	280,961	152,776	154,304	155,847	157,405	
Total Assets	3,839,574	3,193,464	4,065,818	3,861,369	3,290,736	7,002,216	6,675,900	6,366,284	6,072,539	
Liabilities and Stockholders Equity										
Current Liabilities										
Accounts Payable	146,186	231,872	190,057	373,042	247,843	403,729	407,766	411,844	415,962	
Notes Payable	0	0	0	0	0	0	0	0	0	
Other liabilities	18,440	52,635	83,345	4,670	3,315	2,413	2,437	2,462	2,486	
Total Liabilities	164,626	284,507	273,402	377,712	251,158	406,142	410,203	414,305	418,449	
Stockholders Equity										
Common Stock	1,016	1,315	2,096	2,953	3,270	1,685	1,601	1,521	1,445	
Additional Paid-in Capital	85,448,860	85,466,303	87,289,983	88,502,082	90,272,124	93,373,378	95,240,846	97,145,662	99,088,576	
Accumulated Deficit	(81,774,928)	(82,558,661)	(83,499,663)	(85,021,378)	(87,235,817)	(86,778,990)	(93,894,682)	(91,195,206)	(93,435,931)	
Total Stockholders Equity	3,674,948	2,908,957	3,792,416	3,483,657	3,039,577	6,596,073	6,265,695	5,951,977	5,654,089	
Total Liabilities and Stockholders Equity	3,839,574	3,193,464	4,065,818	3,861,369	3,290,736	7,002,216	6,675,900	6,366,284	6,072,539	

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.

SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.